Diabetes Res Clin Pract:体重增加会加大NAFLD和MetS风险,尤其是25-40岁人群

2016-05-18 Seven L 译 MedSci原创

研究者进行了一项研究,探究成年早期(25-40岁)和晚期(>40岁)体重增加对非酒精性脂肪性肝病(NAFLD)和代谢综合征(METS)的影响。该研究纳入了1119名参与者,计算了体重的变化(ΔBW)、BMI变化(ΔBMI)和年体重变化(ΔBW/y),使用多变量回归模型分析这些因素对NAFLD和METS的影响,并通过中介分析探究了ΔBMI和NAFLD联系间的潜在的中介因素。数据显示,整个成年期的ΔB

研究者进行了一项研究,探究成年早期(25-40岁)和晚期(>40岁)体重增加对非酒精性脂肪性肝病(NAFLD)和代谢综合征(METS)的影响。

该研究纳入了1119名参与者,计算了体重的变化(ΔBW)、BMI变化(ΔBMI)和年体重变化(ΔBW/y),使用多变量回归模型分析这些因素对NAFLD和METS的影响,并通过中介分析探究了ΔBMI和NAFLD联系间的潜在的中介因素。

数据显示,整个成年期的ΔBMI、ΔBW和ΔBW/y均与NAFLD和MetS密切相关。成年早期与晚期相比,体重增加与NAFLD的联系更强。对于NAFLD而言,成年早期ΔBMI、ΔBW和ΔBW/y的OR值分别为3.86 (2.25, 6.57)、1.05 (1.02, 1.09)和2.05 (1.29, 3.24);成年晚期这些值分别为1.47 (1.09, 2.02)、1.02 (1.00, 1.06)和1.04 (.99, 1.13)。 胰岛素和HOMA-IR是ΔBMI和NAFLD联系间的潜在的中介因素。成年早期与晚期相比,ΔBMI会导致更高的胰岛素和胰岛素抵抗(IR)。

研究结果表明,成年期体重增加会导致NAFLD和MetS的风险加大,并且成年早期(25-40岁)的体重增加导致的风险大于晚期(>40岁)体重增加。而胰岛素和IR在这之间起着重要的中介作用。

原始出处:

Shanshan Du,Cheng Wang,et al.The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood.Diabetes Res Clin Pract. 2016;doi:10.1016/j.diabres.2016.04.047.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-12-03 lvygwyt2781
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-06-08 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2083886, encodeId=088c2083886c9, content=<a href='/topic/show?id=d3b820e32c' target=_blank style='color:#2F92EE;'>#AFLD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2073, encryptionId=d3b820e32c, topicName=AFLD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Dec 03 19:01:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901374, encodeId=db7c19013e40a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Dec 16 17:01:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895898, encodeId=0f3e1895898a8, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 08 00:01:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637331, encodeId=03f8163e33134, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 27 17:01:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759667, encodeId=a9d81e59667c7, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 11 02:01:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298202, encodeId=dbba1298202b1, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri May 20 10:01:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]

相关资讯

Hepatology:绝经年龄和时长对NAFLD女性肝纤维化的影响

非酒精性脂肪肝炎(NASH)的绝经后女性,与未绝经女性相比,肝纤维化风险更大。女性绝经后雌激素缺乏的持续时间是否会对肝纤维化造成影响呢?研究者对非酒精性脂肪肝(NAFLD)的绝经后女性进行了一项研究,探究绝经年龄、绝经时长对肝纤维化的影响。研究纳入了488名符合以下条件的绝经后NAFLD女性:病理学诊断为NAFLD、自我报道与绝经相关信息。使用多个有序逻辑回归模型(校正和不校正临床混杂因素)评估早

Hepatology:OGIS指数与纤维化评分(NFS)均可预测NAFLD患者纤维化的程度

口服葡萄糖胰岛素敏感指数(OGIS指数)与非糖尿病NAFLD患者的外周胰岛素敏感性密切相关,但目前未在人群中进行验证。本研究旨在评估口服葡萄糖胰岛素敏感指数(OGIS指数)与NAFLD纤维化评分(NFS)是否均可确定肝纤维化程度,以及两者在预测过程中的准确性。 此项研究包括不伴糖尿病的NAFLD患者的验证队列与一个收纳了145名NAFLD患者的独立队列。在验证队列中,胰岛素抵抗分数、胰岛素血糖比

Hepatology:肠道菌群失调可预测NAFLD的严重度

法国昂热大学医院胃肠肝病科Boursier等近日完成的一项研究表明,非酒精性脂肪性肝病(NAFLD)的严重度与肠道菌群失调以及肠道菌群的代谢功能变化有关,拟杆菌属与非酒精性脂肪性肝炎(NASH)独立相关,瘤胃球菌属与显著性肝纤维化独立相关。 该项研究总共纳入经活检证实的57例NAFLD患者,应用粪便标本的16S核糖体RNA基因测序,确定肠道菌群的分类组成,对肠道菌群失调与NAFLD严

Hepatology :NAFLD全球流行病学的全新荟萃分析

美国爱诺华医疗集团费尔法克斯医院肝病中心Younossi等近日完成的一项荟萃分析表明,由于全球肥胖流行引发的代谢问题,非酒精性脂肪性肝病(NAFLD)的临床和经济负担将会非常巨大。 研究者们对1989~2015年的PubMed/MEDLINE数据库进行检索,查找涉及NAFLD流行病学和进展的研究文章,确定NAFLD患者肝细胞肝癌(HCC)、肝硬化、总死亡和肝脏相关死亡的发生率,对非酒精性脂肪

Am J Gastroenterol:缺乏维生素D会增加NAFLD患者的NASH风险

近期发表在American Journal of Gastroenterology的研究称,维生素D缺乏会增加非酒精性脂肪肝(NAFLD)患者的非酒精性脂肪肝炎(NASH)风险。西雅图瑞典医疗中心从事肝脏研究的Kris V. Kowdley博士和同事写道:“近期的研究表明,缺乏维生素D会增加氧化应激和系统性炎症,降低脂联素水平、toll样受体激活和NAFLD...我们对NAFLD患者进行了一项研究

Radiology:NAFLD与高危冠状动脉斑块相关

一项新的研究显示,非酒精性脂肪肝(NAFLD)与高危冠状动脉斑块相关。这是研究者使用冠状动脉CT血管成像评估两者关系后的发现。 研究主要作者麻省总医院和哈佛医学院Stefan B. Puchner博士讲到,“已知动脉粥样硬化与炎症相关,我们想要观察高危斑块与其他系统性炎症状态如NAFLD的关系……有意思的是,两种病理改变都能在CT检查中发现。” Puchner和同事分析ROMICA